908 Devices (NASDAQ:MASS – Get Free Report) had its price objective hoisted by stock analysts at Stifel Nicolaus from $12.00 to $14.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus‘s target price indicates a potential upside of 40.28% from the stock’s previous close.
A number of other brokerages also recently issued reports on MASS. Canaccord Genuity Group began coverage on 908 Devices in a research report on Thursday, September 10th. They set a “buy” rating and a $13.50 price target on the stock. Roth Capital upped their target price on 908 Devices from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 908 Devices in a report on Wednesday, November 4th. Finally, Wall Street Zen lowered 908 Devices from a “buy” rating to a “hold” rating in a research note on Saturday, September 12th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $13.50.
Get Our Latest Stock Report on 908 Devices
908 Devices Stock Performance
Shares of MASS opened at $9.98 on Wednesday. 908 Devices has a 52 week low of $5.03 and a 52 week high of $13.35. The firm has a market cap of $412.47 million, a P/E ratio of -10.51 and a beta of 0.66. The firm’s 50-day simple moving average is $11.19 and its 200 day simple moving average is $8.51.
908 Devices (NASDAQ:MASS – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. The firm had revenue of $18.95 million for the quarter, compared to analysts’ expectations of $18.31 million. 908 Devices had a negative net margin of 56.96% and a negative return on equity of 12.54%. As a group, equities analysts forecast that 908 Devices will post -0.59 earnings per share for the current year.
Insider Activity at 908 Devices
In related news, CFO Joseph Griffith, IV sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $13.03, for a total transaction of $65,150.00. Following the completion of the transaction, the chief financial officer directly owned 116,497 shares in the company, valued at $1,517,955.91. This represents a 4.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP John Kenneweg sold 5,257 shares of the stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $10.22, for a total transaction of $53,726.54. Following the completion of the transaction, the senior vice president directly owned 57,784 shares of the company’s stock, valued at approximately $590,552.48. The trade was a 8.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 134,115 shares of company stock valued at $1,473,296. 28.20% of the stock is owned by insiders.
Institutional Trading of 908 Devices
Institutional investors have recently modified their holdings of the business. AWM Investment Company Inc. acquired a new position in shares of 908 Devices in the second quarter worth approximately $42,454,000. BlackRock Inc. acquired a new position in shares of 908 Devices during the second quarter valued at about $16,915,000. First Light Asset Management LLC increased its position in 908 Devices by 25.6% in the 1st quarter. First Light Asset Management LLC now owns 6,072,563 shares of the company’s stock valued at $37,164,000 after buying an additional 1,236,377 shares in the last quarter. Granahan Investment Management LLC raised its stake in 908 Devices by 662.6% during the 1st quarter. Granahan Investment Management LLC now owns 695,070 shares of the company’s stock worth $4,254,000 after buying an additional 603,929 shares during the period. Finally, Meros Investment Management LP acquired a new position in 908 Devices during the 2nd quarter worth approximately $3,143,902. Institutional investors own 88.06% of the company’s stock.
908 Devices News Summary
Here are the key news stories impacting 908 Devices this week:
- Positive Sentiment: Third-quarter revenue rose 35% year over year to a record $18.95 million, topping the $18.31 million consensus estimate. The company also reported record device shipments. 908 Devices Q3 2026 results
- Positive Sentiment: The quarterly loss of $0.11 per share was narrower than analysts’ expected $0.15 loss and the $0.15 loss reported a year earlier. Zacks earnings report
- Neutral Sentiment: 908 Devices forecast full-year 2026 revenue of $68.5 million to $70.0 million, close to the $69.1 million analyst consensus. The outlook therefore offered little apparent upside surprise.
- Negative Sentiment: The company continues to post substantial losses, including a negative net margin of 56.96%. Investors may be focused on the path to profitability despite the revenue and earnings-per-share beats.
About 908 Devices
908 Devices Inc. is a Boston-based analytical technology company that develops purpose-built mass spectrometers for use outside traditional laboratory environments. Its instruments are designed to provide rapid chemical and biological analysis in the field, helping users identify unknown substances and make time-sensitive decisions. The company’s product portfolio includes the MX908 handheld mass spectrometer, which is used to detect and identify chemical threats, explosives, narcotics and other hazardous materials.
Featured Stories
- Five stocks we like better than 908 Devices
- The Trade Desk Beats on Revenue, But the Fine Print Matters
- Poll Reveals: Which States Are Most Prepared for a Crisis? [2026]
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.
